(+)-JQ1 is a selective and potent inhibitor of Bromodomain and Extra-Terminal motif (BET) proteins. These are important epigenetic regulators facilitating the transcription of genes in chromatin areas linked to acetylated histones. (+)-JQ1 engages the bromodomain pocket in a manner that is competitive with acetylated peptide binding, thereby causing the displacement of BET proteins from chromatin. However, the inhibitor’s half life is only one hour, so it has short-lasting effects.

MK-912 is non-specific alpha-2 adrenergic receptor antagonist, with high affinity for the alpha-2-A, alpha-2B, and alpha-2C variants. Originally developed by Merk & Co, it has been investigated for potential therapeutic properties for the treatment of depression and diabetes. MK-912 is also regularly used as a molecular probe in biomedical studies seeking information about alpha-2 adrenergic receptors.